A number of laboratory and clinical studies have shown that interleukin-6 is the principal mediator of the acute phase protein response. In this study the relationship between serum concentrations of interleukin-6 and C-reactive protein in acute pancreatitis are examined and the ability of interleukin-6 to discriminate between severe and mild attacks is assessed. We have studied 24 patients (10 severe and 14 mild). Serum samples were collected on admission, six hourly for 48 hours and then 12 hourly for a further three days. 'When the areas under the curves of individual patients were compared there was a strong correlation between the total production of interleukin-6 and C-reactive protein (r=0.73) (Spearman rank correlation) and peak interleukin-6 and C-reactive protein concentrations (r=0-75), suggesting a close relationship between interleukin-6 and C-reactive protein production. Both on admission and peak interleukin-6 concentrations were significantly higher in patients with severe than mild disease. There was no significant difference in on admission C-reactive protein concentrations, although significant differences were seen when peak concentrations were considered. Utilising a peak interleukin-6 concentration of >130 u/ml, we were able to distinguish between severe and mild attacks of acute pancreatitis with a sensitivity of 100% and specificity of 71%. These figures were comparable with those for peak C-reactive protein, a C-reactive protein of 
compared there was a strong correlation between the total production of interleukin-6 and C-reactive protein (r=0.73) (Spearman rank correlation) and peak interleukin-6 and C-reactive protein concentrations (r=0-75), suggesting a close relationship between interleukin-6 and C-reactive protein production. Both on admission and peak interleukin-6 concentrations were significantly higher in patients with severe than mild disease. There was no significant difference in on admission C-reactive protein concentrations, although significant differences were seen when peak concentrations were considered. Utilising a peak interleukin-6 concentration of >130 u/ml, we were able to distinguish between severe and mild attacks of acute pancreatitis with a sensitivity of 100% and specificity of 71%. These figures were comparable with those for peak C-reactive protein, a C-reactive protein of In order to examine the time course of interleukin-6 and C-reactive protein production in patients with acute pancreatitis, it was necessary to correlate serum concentrations from the time of onset of symptoms rather than from the time ofadmission. As it was not possible to control the delay between the onset of symptoms and admission to hospital, it was not possible to obtain samples at exactly corresponding tissue points from different patients. Samples were therefore allocated to one of eight groups. These were <24 hours, 25- 18 The area under the curve of interleukin-6 and C-reactive protein represents the magnitude of the response during the study period. The areas under curves (AUC) were calculated from the formula:-
Where t=the time after admission, y=the concentration at time t, i=initial time points and n represents the last time point.
The areas under the curves were divided by the number of hours in order to take account of the different times for which samples had been collected from individual patients. Results 
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Serum concentrations of interleukin-6 rose during the first 24 hours after the onset of symptoms in all patients and peaked between 24 and 36 hours (Fig 1) . The magnitude of the interleukin-6 response (represented by the area under the response curve) differed between patient groups. In patients with severe disease the median response was 240 u/ml/h (range 72-560 u/ml/h) and in the mild group 38 u/ml/h (range 18-140 u/ml/h). These differences were highly significant (95% confidence interval (CI)=92 to 232 u/ml/h, p<0 001). Peak inter- Time from onset of symptoms (h) the first 24 hours to peak between 36 and 48 Median interleukin-6 and C-reactive protein concentrations in the serum of10
hours after the onset of symptoms (Fig 1) . The fith severe and 14 with mild acute pancreatitis.
magnitude of the C-reactive protein response noted when peak concentrations were considered a (95% CI=74 to 214 mg/I, p<0 0006). The sensitivity, specificity, positive and negative predictive values and percentage correct for a peak interleukin-6 concentration of >130 u/ml and a C-reactive protein concentration of >150 mg/l are displayed in Table II Figure 2 ) and skin incision for a variety of surgical procedures. between peak interleukin-6 and C-reactive As Nijsten et a120 tell us little about the severity of protein concentrations (r=0-75, Figure 3) . the burns (if patients had only mild burns the On admission and peak concentrations of peak interleukin-6 concentration would be small interleukin-6 were significantly greater in and short lived) and only took samples on a daily patients with severe than mild disease (95% basis, it is probable that peak interleukin-6 CI=33-9 to 129 u/ml, p<0O008 and 95% CI= 134 concentrations have been missed. Further to 593, p<0005) respectively.
evidence that peak interleukin-6 concentrations On admission concentrations of C-reactive may occur later in inflammatory disease comes protein were not significantly greater in patients from animal work. Geiger et al23 injected one Peak serum with severe than mild disease (CI= -96 to4 mg/I, group of rats with human recombinant interin-6 and C-reactive p<O-125) although significant differences were leukin-6 and one with turpentine (a means of mncentrations in 10 inducing an acute inflammatory reaction) and viith severe and 14anaueifamtrraco) acutevpancreatitis.
then compared the time to maximal mRNA production for a number of acute phase proteins. In those injected with interleukin-6 peak concentrations of acute phase protein mRNAs were * seen within four hours, whereas there was a delay of [16] [17] [18] [19] [20] [21] [22] [23] [24] Better separation between the patient groups was noted when peak concentrations were considered, the sensitivity and specificity of interleukin-6 and C-reactive protein being comparable, and somewhat better than previous reports of the mutlifactorial scoring systems. 45 Speculation that interleukin-6 may be useful in clinical practice as a severity indicator in acute pancreatitis is dependent on results being available within a few hours of sample collection. The major drawback of the interleukin-6 bioassay used here is the long turn around time of five days. Several commercial manufacturers, however, have recently developed and marketed immunoassays for interleukin-6 (Quantikine Human interleukin-6, British Bio-technology Ltd, Abingdon, Oxon; Biokine interleukin-6 test kit, T Cell Sciences, Cambridge; Co-eliza interleukin-6, Kabi Diagnostica, Sweden). These assays have turnaround times of less than six hours and consequently, the methodology is now available to produce interleukin-6 results within the time scale necessary for them to be of value clinically. It should be noted, however, that we have no direct experience of any of these assays.
